Short answer
Aura Biosciences, Inc. (AURA) filed its Q2 2026 10-Q quarterly report on Aug 11, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$46M
- −68.9% YoY · −35.5% QoQ
- EPS (diluted)
- −$0.48
- −4.3% YoY · +4.0% QoQ
Source: XBRL data from the Aura Biosciences, Inc. (AURA) Q2 2026 10-Q on SEC EDGAR. USD.
Aura Biosciences, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Net losses $79.3 million for six months ended June 30, 2026, with accumulated deficit $559.7 million
- Cash, cash equivalents, and marketable securities expected to fund operations into first half of 2029
- Bel-sar pivotal Phase 3 enrollment complete, but topline data not expected until second half of 2027
- Bel-sar’s drug-device-laser combination creates additional regulatory approval uncertainty
- Bel-sar remains the only product candidate, concentrating development and commercialization risk
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Aura Biosciences, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.